US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Stage

0.3754

0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

52wk High:9.50

52wk Low:0.2700

Shares:28.91M

Float Shares:20.31M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.05

Dividend Rate:13.32%

EPS(TTM):-3.3321

EPS(LYR):-3.1264

ROE:-44.60%

ROA:-3.54%

PB:0.07

PE(LYR):-0.12

Loading ...

Overview Company News Filings

Press Release: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients

MT Newswires Live

NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program

Early-Stage Venture Funds Have to Be Big to Compete, VC Says -- Market Talk

BridgeBio: De-Risked Achondroplasia Program and Expanding Late-Stage Rare-Disease Portfolio Underpin Buy Rating and Blockbuster Growth Outlook

Sun Pharma’s GL0034 Diabetes Trial: Early-Stage Data Catalyst in a Crowded Metabolic Market

Tietoevry Calls 2026 AGM and Proposes Two-Stage Dividend of EUR 0.88 per Share

American Airlines Staff To Stage Protest, Demand 'Accountability' After Historic No-Confidence Vote On CEO Robert Isom

Alpha HPA Says Solvent Extraction Tanks Delivered to Site for Queensland Project Stage Two Construction; Shares Fall 3%

MT Newswires Live

GBM Resources Begins Stage Two Drilling Program at Queensland Project, Shares Jump 8%

MT Newswires Live

Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs

Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026

Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

Stoke Therapeutics Initiates Early-Stage Study for Genetic Vision Loss Treatment

MT Newswires Live

Lindian Resources Starts Second-Stage Resource Definition Drilling at Malawi Project

MT Newswires Live

Immatics’ treatment of Stage II and higher CM granted FDA orphan designation

Sally Beauty: Early-Stage Growth Initiatives and Margin Expansion Underpin Buy Rating and Raised $20 Price Target

Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial

MT Newswires Live

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Ucommune Shareholders Approve Major Capital Increase and Multi-Stage Reverse Split Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"05-08 16:00:00 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773302400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611156454","title":"Press Release: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2611156454","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611156454?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:30","pubTimestamp":1770982200,"startTime":"0","endTime":"0","summary":"-- Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds --. -- Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Transition into a Commercial Organization --. -- Simona Skerjanec, Former SVP, Global Head of Neuroscience and Rare Diseases at Roche, Elevated to Interim Chairperson of the Board of Directors --. -- Thor Nagel, Principal at BVF Partners L.P., Joins Board of Directors --. -- Simona Skerjanec and Dr. Daniel Vitt to Lead Search for CEO with Commercial Background --. The proceeds of this financing are expected to support Immunic's strategic transition from a research and development (R&D)-focused company into a fully integrated commercial entity. In the coming months, the company will prioritize:. With these pivotal programs underway, Immunic is positioning itself to become a leading innovator in next--generation oral the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","LU0320765646.SGD","LU1720051108.HKD","IE00BKVL7J92.USD","BK4581","LU1989772923.USD","LU0106831901.USD","LU0234570918.USD","LU1720051017.SGD","LU0314104364.USD","LU1244550221.USD","LU2347655156.SGD","LU2028103732.USD","LU1791710400.SGD","BK4585","BK4588","BK4534","LU0971096721.USD","LU1244550494.USD","LU1074936037.SGD","LU0006306889.USD","LU0912757837.SGD","LU0158827948.USD","USD","LU1668664300.SGD","LU0098860793.USD","BK4504","SSI","LU2089283258.USD","BK4127","IE00BZ1G4Q59.USD","LU0267386448.USD","LU1732800096.USD","LU0795875169.SGD","LU1732799900.SGD","LU0158827781.USD","LU2111349929.HKD","LU1548497426.USD","LU0225283273.USD","IMUX","LU0557290698.USD","LU0795875086.SGD","LU0882574139.USD","LU1989772840.SGD","AAQC","LU0528227936.USD","LU1162221912.USD","LU1363072403.SGD","LU1791710582.SGD","BK4139"],"gpt_icon":0},{"id":"2611533581","title":"Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2611533581","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611533581?lang=en_us&edition=fundamental","pubTime":"2026-02-13 18:28","pubTimestamp":1770978531,"startTime":"0","endTime":"0","summary":"Novartis  said Friday that final results from a phase III study supported a slowing decline in kidney function in adults with IgA nephropathy, a progressive autoimmune kidney disease, who were treated with Vanrafia, or atrasentan.Data showed \"clinically meaningful results\" with Vanrafia, compared with placebo in estimated glomerular filtration rate change from baseline at the end of study treatment at week 132, the company said.Novartis said safety was consistent with prior findings.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","BK4588","BK4585","BK4578","IE0009355771.USD","LU0070302665.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD","BK4007","LU0211331839.USD","BK4532","IE0002141913.USD","NVS","IE00B2B36J28.USD","SSI"],"gpt_icon":0},{"id":"2611034529","title":"NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2611034529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611034529?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:53","pubTimestamp":1770933180,"startTime":"0","endTime":"0","summary":"The latest announcement is out from NervGen Pharma ( ($TSE:NGEN) ). NervGen Pharma, a clinical-stage biopharmaceutical company developing neurorepa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nervgen-pharma-cfo-to-retire-as-company-advances-late-stage-sci-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nervgen-pharma-cfo-to-retire-as-company-advances-late-stage-sci-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2611908588","title":"Early-Stage Venture Funds Have to Be Big to Compete, VC Says -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2611908588","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611908588?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:24","pubTimestamp":1770931440,"startTime":"0","endTime":"0","summary":"1624 ET - Venture firms that invest in seed-stage startups need much more capital to compete in the current market, said Benjamin Sun, partner and co-chief investment officer at Primary Venture Partners. Primary, for example, raised $625 million across two new funds, almost 50% more than in its prior fundraising in 2023. \"We need to make sure we can show up and compete not only with small seed funds but with the big multistage and megafunds, as well,\" Sun said. Venture firms put more than $20 billion into seed-stage startups in the U.S. last year, compared to about $5 billion a decade ago, according to the PitchBook-NVCA Venture Monitor report. Sun said valuations and deal sizes, as well as the size of ultimate exits have grown. \"Seed is just a lot bigger now and more competitive and founders have more choice,\" Sun said. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6062","SSI","LU1815336091.USD","SG9999006266.SGD","SG9999004220.SGD","LU0757428866.USD","SG9999014492.USD","VC","SG9999014484.SGD","BK6515","IE00BZ199S13.USD","SG9999008742.SGD","BK4124","SG9999001135.SGD","SG9999004360.SGD","SG9999000475.SGD","SG9999001846.SGD","V03.SI"],"gpt_icon":0},{"id":"2611971043","title":"BridgeBio: De-Risked Achondroplasia Program and Expanding Late-Stage Rare-Disease Portfolio Underpin Buy Rating and Blockbuster Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2611971043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611971043?lang=en_us&edition=fundamental","pubTime":"2026-02-13 03:15","pubTimestamp":1770923719,"startTime":"0","endTime":"0","summary":"Jefferies analyst Andrew Tsai maintained a Buy rating on BridgeBio Pharma today and set a price target of $100.00. Andrew Tsai has given his Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bridgebio-de-risked-achondroplasia-program-and-expanding-late-stage-rare-disease-portfolio-underpin-buy-rating-and-blockbuster-growth-outlook-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bridgebio-de-risked-achondroplasia-program-and-expanding-late-stage-rare-disease-portfolio-underpin-buy-rating-and-blockbuster-growth-outlook-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2611377975","title":"Sun Pharma’s GL0034 Diabetes Trial: Early-Stage Data Catalyst in a Crowded Metabolic Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2611377975","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611377975?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:31","pubTimestamp":1770913902,"startTime":"0","endTime":"0","summary":"Sun Pharmaceutical Industries Limited ($IN:SUNPHARMA) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Ltd. is ru...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sun-pharmas-gl0034-diabetes-trial-early-stage-data-catalyst-in-a-crowded-metabolic-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sun-pharmas-gl0034-diabetes-trial-early-stage-data-catalyst-in-a-crowded-metabolic-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2610924295","title":"Tietoevry Calls 2026 AGM and Proposes Two-Stage Dividend of EUR 0.88 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610924295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610924295?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:55","pubTimestamp":1770904543,"startTime":"0","endTime":"0","summary":"TietoEVRY ( ($GB:0KG0) ) has shared an update. Tietoevry has convened its shareholders to the Annual General Meeting, scheduled for 24 March 2026 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tietoevry-calls-2026-agm-and-proposes-two-stage-dividend-of-eur-0-88-per-share?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tietoevry-calls-2026-agm-and-proposes-two-stage-dividend-of-eur-0-88-per-share?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4195","BK4229","AGM"],"gpt_icon":0},{"id":"2610249229","title":"American Airlines Staff To Stage Protest, Demand 'Accountability' After Historic No-Confidence Vote On CEO Robert Isom","url":"https://stock-news.laohu8.com/highlight/detail?id=2610249229","media":"Benzinga","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610249229?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:41","pubTimestamp":1770903660,"startTime":"0","endTime":"0","summary":"The Association of Professional Flight Attendants (APFA), representing over 28,000 flight attendants of the American Airlines Group (NYSE: AAL), will hold a protest on Thursday, calling for \"accountability and leadership change.\"","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/12/Phoenix--Az---December-7--2019-Photo-Of-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/12/Phoenix--Az---December-7--2019-Photo-Of-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/travel/26/02/50574435/american-airlines-staff-to-stage-protest-demand-accountability-after-historic-no-confidence-vote-on-ceo-robert-isom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/travel/26/02/50574435/american-airlines-staff-to-stage-protest-demand-accountability-after-historic-no-confidence-vote-on-ceo-robert-isom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4585","BK4008","SSI","BK4547","BK4500","BK4588","AAL"],"gpt_icon":0},{"id":"2610957659","title":"Alpha HPA Says Solvent Extraction Tanks Delivered to Site for Queensland Project Stage Two Construction; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610957659?lang=en_us&edition=fundamental","pubTime":"2026-02-12 09:45","pubTimestamp":1770860757,"startTime":"0","endTime":"0","summary":"Alpha HPA  said solvent extraction tanks were delivered to the site for the construction of stage two of the HPA First project in Queensland, according to a Thursday statement.The solvent extraction circuit is a key part of the design to produce ultra-high-purity aluminum materials.Its shares fell 3% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["A4N.AU","BK7017","SSI"],"gpt_icon":0},{"id":"2610998251","title":"GBM Resources Begins Stage Two Drilling Program at Queensland Project, Shares Jump 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610998251","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610998251?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:18","pubTimestamp":1770855535,"startTime":"0","endTime":"0","summary":"GBM Resources  began a multi-rig 50,000-meter stage two drilling program at the Twin Hills project in Queensland, according to a Thursday Australian bourse filing.The program consists of around 20,000 meters of reverse circulation and 30,000 meters of diamond drilling. The drilling will prioritise the definition and expansion of near-surface mineralisation suitable for open-pit mining.Its shares climbed 8% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","GBM.AU","BK7104"],"gpt_icon":0},{"id":"2610964354","title":"Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610964354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610964354?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:45","pubTimestamp":1770846337,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Richard Law moved shares of Bicara Therapeutics (BCAX) to Neutral rating and $14 price target from the firm’s Early-Stage Bio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-moved-to-neutral-from-early-stage-biotech-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-moved-to-neutral-from-early-stage-biotech-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","SSI"],"gpt_icon":0},{"id":"2610521419","title":"Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610521419","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610521419?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:45","pubTimestamp":1770828321,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Tyler Van Buren has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-gilead-solid-core-growth-conservative-guidance-and-late-stage-pipeline-upside-into-2026-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-gilead-solid-core-growth-conservative-guidance-and-late-stage-pipeline-upside-into-2026-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2610897952","title":"Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610897952","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610897952?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:31","pubTimestamp":1770827515,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a mid-stage study called “A Phase...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-advances-oral-crohns-disease-drug-tak-279-with-active-mid-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-advances-oral-crohns-disease-drug-tak-279-with-active-mid-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4007","TAK"],"gpt_icon":0},{"id":"2610558199","title":"Stoke Therapeutics Initiates Early-Stage Study for Genetic Vision Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610558199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610558199?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:12","pubTimestamp":1770819120,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics  said Wednesday that the first patient has received a dose in an early-stage trial of STK-002 for the treatment of Autosomal Dominant Optic Atrophy, an inherited vision loss condition.The open-label study's primary objective will be to evaluate the safety and tolerability of the investigational medicine in patients between the ages of 6 and 55, the company said.Researchers plan to monitor changes in visual function, eye structure, and quality of life as secondary goals of the clinical program, the company added.Stoke Therapeutics said the trial is currently enrolling participants with a confirmed genetic mutation linked to the condition in Germany and the UK, with additional European sites expected to activate in the coming months.The company also said the dose escalation for the initial four groups is expected to continue through this year and into early next year.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK4007","STOK","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2610704086","title":"Lindian Resources Starts Second-Stage Resource Definition Drilling at Malawi Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2610704086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610704086?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:14","pubTimestamp":1770768843,"startTime":"0","endTime":"0","summary":"Lindian Resources  started a second-stage resource definition drilling and mine geotechnical program at the Kangankunde project in Malawi to convert up to 40 million tonnes of current inferred mineral resource material to indicated category, according to a Wednesday filing with the Australian bourse.The program covers roughly 3,400 meters of diamond core drilling and 2,700 meters of reverse circulation drilling, with drilling expected to run through April, the filing said.Assay results are expected in May, with an updated resource model planned for June, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK7095","LIN.AU"],"gpt_icon":0},{"id":"2610527670","title":"Immatics’ treatment of Stage II and higher CM granted FDA orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610527670","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610527670?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:30","pubTimestamp":1770766213,"startTime":"0","endTime":"0","summary":"Immatics (IMTX)’ treatment of Stage II and higher cutaneous melanoma, in human leukocyte antigen-A 02:01-positive patients, was granted FDA orphan ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immatics-treatment-of-stage-ii-and-higher-cm-granted-fda-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immatics-treatment-of-stage-ii-and-higher-cm-granted-fda-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CM","SSI","BK4207","IMTX","BK4139"],"gpt_icon":0},{"id":"2610664234","title":"Sally Beauty: Early-Stage Growth Initiatives and Margin Expansion Underpin Buy Rating and Raised $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610664234?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:55","pubTimestamp":1770724532,"startTime":"0","endTime":"0","summary":"Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Sally Beauty, boosting the price target to $20.00. Susan Anderson has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sally-beauty-early-stage-growth-initiatives-and-margin-expansion-underpin-buy-rating-and-raised-20-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sally-beauty-early-stage-growth-initiatives-and-margin-expansion-underpin-buy-rating-and-raised-20-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SBH","SSI"],"gpt_icon":0},{"id":"2610656513","title":"Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656513","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656513?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:04","pubTimestamp":1770645869,"startTime":"0","endTime":"0","summary":"Nuvation Bio  said Monday that it has finalized a protocol amendment to upgrade an ongoing study of its cancer drug, safusidenib, from a mid-stage to a late-stage trial.The expanded registrational study now includes patients with high-risk or high-grade IDH1-mutant astrocytoma who have completed standard care, the company said.Participant enrollment for the trial will increase from 100 to 300 patients across the US, China, and Australia, Nuvation Bio said.The updated protocol also introduces a new group to evaluate the treatment in patients with grade 3 IDH1-mutant oligodendroglioma who have not received chemotherapy or radiation, the company said.Shares of the company were up less than 1% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUVB","SSI","BK4007"],"gpt_icon":0},{"id":"2610655338","title":"Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655338","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610655338?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:30","pubTimestamp":1770643800,"startTime":"0","endTime":"0","summary":"Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Austra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234525/0/en/Oragenics-Targets-Projected-9-Billion-Market-by-Advancing-First-and-Only-Clinical-Stage-Concussion-and-Mild-Traumatic-Brain-Injury-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","SSI","CDC","OGEN","BK4139"],"gpt_icon":0},{"id":"2610365823","title":"Ucommune Shareholders Approve Major Capital Increase and Multi-Stage Reverse Split Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365823","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365823?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:57","pubTimestamp":1770641865,"startTime":"0","endTime":"0","summary":"Ucommune International ( ($UK) ) has provided an update. On 9 February 2026, Ucommune International Ltd held an extraordinary general meeting in Be...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ucommune-shareholders-approve-major-capital-increase-and-multi-stage-reverse-split-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ucommune-shareholders-approve-major-capital-increase-and-multi-stage-reverse-split-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}